



# European Alliance for Personalised Medicine (EAPM)

Bridging Science, Policy, and Practice for Equitable Innovation in Health

## Executive Summary

In 2026, the European Alliance for Personalised Medicine (EAPM) will advance measurable health-system transformation across Europe ensuring that innovation in personalised medicine translates into timely access to diagnostics and treatment for every patient.

Over the past decade, EAPM has built trusted relationships with the European Parliament, the European Commission, Council Presidencies, and national governments, providing a permanent platform where science and policy meet. This trust allows EAPM to help shape policies that make research and innovation deliver real-world health impact.

EAPM's mission is to integrate advanced molecular diagnostics, digital pathology, liquid biopsy, and AI-enabled decision support into healthcare systems across all Member States.

Through its collaboration in EU4Health, Horizon Europe, and the Innovative Health Initiative (IHI), EAPM transforms advances in genomics, biomarkers, and data science into policy frameworks for implementation. Its 2026 priorities align with the EU's call to "Choose Europe for Life Sciences" and support the structural competitiveness agenda outlined in the Draghi and Letta reports.

A core priority in 2025–2026 is to support the implementation of the new EU Biotech Act ensuring that biotechnology, diagnostics, and digital tools can move from laboratory to health system faster, safely, and equitably.

In parallel, EAPM will contribute to the updating of the EU Council Conclusions on Cancer Screening and related health policies, ensuring that the latest advances in diagnostics, data, and AI are reflected in prevention, early detection, and care frameworks.

## Key Deliverables

- **Policy and governance frameworks** that enable faster integration of diagnostics and biotech innovation into healthcare systems.
- **Equity and access indicators** to measure patient reach and national readiness.
- **Policy recommendations** to update EU Council Conclusions and implement the Biotech Act in health policy contexts.

With flagship forums in Brussels and Dublin, a High-Level Advocacy Conference in 2026, and presence at major scientific congresses (EHA, ESC, ERS, ESP, ESMO), EAPM will help ensure that Europe's innovation and competitiveness agenda delivers tangible health benefits.

---

# Key Achievements – 2025

## Strategic Impact

2025 marked a breakthrough in translating evidence into policy. EAPM strengthened its standing as Europe's trusted interface between EU institutions, national governments, scientific societies, and patient groups, supporting measurable progress toward equitable access to innovation.

## Policy and Advocacy

- Influenced European Parliament and Council discussions on data, diagnostics, biotech, and equitable access.
- Delivered key events — including Every Second Counts: *Modernising Cancer Screening* — shaping Parliament's recommendations on early detection.
- Contributed to the European Commission's preparatory work for updating the Council Conclusions on Screening, and engaged on parallel files including the Biotech Act, AI Act, European Health Data Space, Pharmaceutical Legislation, and HTA Regulation — ensuring coherence across Europe's health innovation architecture.
- Advanced the “Choose Europe for Life Sciences” narrative, promoting an ecosystem that combines research excellence with equitable access.

## Science-Policy Integration

- Advanced deployment of NGS and molecular diagnostics through the SPARC, CAN.HEAL, and BEACON projects.
- Published peer-reviewed work in *JCO Global Oncology*, *Diagnosis*, and *Healthcare* on system readiness and access disparities.
- Introduced validated frameworks for AI-assisted pathology and liquid biopsy integration, now referenced in EU-level health innovation discussions including the Biotech Act.

## Engagement and Network Growth

- Engaged **over 250 policymakers, researchers, and advocates** in structured EU and national dialogues.
- Strengthened collaboration with **Council Presidencies** and national ministries of health.
- Reinforced its role as a **policy driver and implementation catalyst**, linking research investment to patient access.

## Outcome:

By the end of 2025, EAPM had positioned itself as a cornerstone of the EU health-policy ecosystem helping Member States turn research outcomes into accessible, affordable, and equitable diagnostics and treatments.



---

# Projects and Deliverables – 2026

## Flagship Project: Advancing Personalised Medicine – Pathways for Future Innovation

In 2026, EAPM will launch its flagship initiative:

- **Advancing Personalised Medicine: Pathways for Future Innovation**, a comparative, evidence-based assessment of how European health systems are integrating new technologies in cancer and chronic disease care.

The project will set a **benchmark for system readiness**, identifying best practices to ensure that new diagnostics, therapies, and biotech innovations reach patients faster and more equitably. It supports both the **implementation of the EU Biotech Act and the updating of the Council Conclusions on Cancer Screening**, while aligning with the EU's **Data Space, AI governance, and HTA coordination** initiatives.

### Nine Study Areas

**MRD, Pharmacogenomics, Digital Pathology, Brain Health, Obesity, Cardiovascular, Diabetes, Liquid Biopsy, and AI-Driven Cancer Screening**

### Objectives

- **Benchmark adoption and performance** across Member States using EAPM's maturity framework.
- **Evaluate progress** across governance, infrastructure, workforce, evidence, financing, and equity.
- **Identify transferable policy lessons** for scaling innovation in real-world systems.
- **Translate evidence into action** via factsheets and concise policy papers.

### Findings will inform:

- Implementation of the **EU Council Conclusions on Personalised Medicine**,
- The **updated Council Conclusions on Cancer Screening**,
- The **implementation of the Biotech Act**, and
- Broader frameworks including the **AI Act, European Health Data Space, and HTA cooperation** embedding diagnostic and treatment innovation into Europe's prevention and care architecture.

### Deliverables

- **9 Comparative Studies** on system maturity and adoption.
- **10 Country Factsheets** visualising readiness and access.
- **6 Policy Papers** outlining policy and regulatory actions.
- **EU Synthesis Report** consolidating cross-country findings and lessons.

### Expected Impact

- Deliver Europe's first **comprehensive readiness map** for biotech and precision-health adoption.
- Guide the **implementation of the Biotech Act** in synergy with data, AI, and access frameworks.
- Improve **access to diagnostics and treatments** through integrated policy alignment.
- Strengthen Europe's global leadership in life sciences, access equity, and innovation



---

## Advocacy and Engagement – 2026

EAPM will convene a **High-Level Advocacy Conference in 2026**, gathering EU and national policymakers, regulators, biotech innovators, clinicians, and patient representatives to reinforce alignment across Europe's health-innovation ecosystem.

### The conference will:

- Advance the **update of the Council Conclusions on Screening** and related access frameworks.
- Facilitate dialogue on **Biotech Act implementation**, ensuring alignment with health-system realities.
- Promote strategies to **improve access to diagnostics and treatments**, reducing inequities across Member States.
- Highlight **systemic frameworks** to integrate innovation sustainably into health systems.
- Reinforce Europe's global identity through the “**Choose Europe for Life Sciences**” initiative.

This event will complement EAPM's Brussels and Dublin policy forums and its participation in major scientific societies, connecting evidence, advocacy, and impact.

## Strategic Value for Funders

EAPM is a long-standing, trusted partner of EU institutions and national governments.

### For funders and partners, engagement offers:

- Alignment with **core EU health-policy priorities** the Biotech Act, Council Conclusions, Data Space, AI, and access to care.
- **High visibility** in major policy and advocacy platforms.
- **Concrete, measurable deliverables** on access, readiness, and innovation adoption.
- A unique opportunity to help **shape the frameworks that determine how innovation reaches patients**.

## Closing Message

EAPM ensures that Europe's scientific excellence translates into equitable access. Working closely with **EU institutions, Council Presidencies, and national governments**, EAPM connects policy ambition with clinical reality — ensuring that innovation becomes care.

**“From pilots to policy, EAPM ensures that innovation becomes access and that Europe leads where science meets regulation and society.”**

